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An increase in α-synuclein levels due to gene duplications/triplica-
tions or impaired degradation is sufﬁcient to trigger its aggrega-
tion and cause familial Parkinson disease (PD). Therefore, lowering
α-synuclein levels represents a viable therapeutic strategy for the
treatment of PD and related synucleinopathies. Here, we report
that Polo-like kinase 2 (PLK2), an enzyme up-regulated in synu-
cleinopathy-diseased brains, interacts with, phosphorylates and
enhances α-synuclein autophagic degradation in a kinase activ-
ity-dependent manner. PLK2-mediated degradation of α-synuclein
requires both phosphorylation at S129 and PLK2/α-synuclein com-
plex formation. In a rat genetic model of PD, PLK2 overexpression
reduces intraneuronal human α-synuclein accumulation, suppresses
dopaminergic neurodegeneration, and reverses hemiparkinsonian
motor impairments induced by α-synuclein overexpression. This
PLK2-mediated neuroprotective effect is also dependent on PLK2
activity and α-synuclein phosphorylation. Collectively, our ﬁndings
demonstrate that PLK2 is a previously undescribed regulator of
α-synuclein turnover and that modulating its kinase activity could
be a viable target for the treatment of synucleinopathies.
adeno-associated virus | animal model | serum inducible kinase
Parkinson disease (PD) is a neurodegenerative disorder char-acterized by the progressive neuronal loss in different brain
regions, including the dopaminergic (DA) neurons of the sub-
stantia nigra pars compacta (SNc) (1, 2). Pathologically, PD is
characterized by the presence, in surviving DA neurons, of in-
tracellular inclusions called Lewy Bodies (LBs) and Lewy Neurites
(LNs) (3). These ﬁbrillar aggregates are mainly composed of the
presynaptic protein α-synuclein (α-syn) (4). Converging evidence
from pathologic, genetic, biochemical, and biophysical studies
supports the hypothesis that α-syn accumulation and misfolding
play a central role in the pathogenesis of PD and related disorders,
which are altogether referred to as synucleinopathies (5).
Although α-syn is constitutively phosphorylated at low levels
(<4%) at S129 (pS129) in normal brains (6–8), a clear accumula-
tion of pS129 (>90%) is found in LBs (8, 9) and in the brain of
animal models of synucleinopathies (7, 10–12). The roles of this
major posttranslational modiﬁcation in regulating α-syn physiology
and LB formation and/or neurodegeneration in PD remain elusive.
Recently, our group and others (13–15) demonstrated that Polo-
like kinase 2 (PLK2), a serine/threonine kinase playing a central
role in cell division, oncogenesis, and synaptic regulation in the
adult brain (16–19), efﬁciently phosphorylates α-syn, with an ex-
clusive preference for the S129 site. Unlike other kinases that were
reported to partially phosphorylate α-syn at S129, PLK2 phos-
phorylates α-syn with quantitative conversion in vitro (>95%) and in
mammalian cell lines (13–15).
Interestingly, PLK2 expression levels are signiﬁcantly up-regu-
lated in the midbrain of aged monkeys and correlate with in-
creased pS129 levels in dopaminergic neurons (20). Furthermore,
neuropathological analysis of diseased brains and tissues from
α-syn transgenic animal models of synucleinopathies also showed
a signiﬁcant up-regulation of PLK2 protein levels, and colocali-
zation with pS129 in neuronal cell bodies and terminals (13).
Together, these observations suggest that PLK2 might play an
important role in the modulation of α-syn physiology in normal
and diseased conditions. However, whether this increase in PLK2
contributes to α-syn aggregation and neurodegeneration in PD or
reﬂects an active cellular response to prevent these processes
remains unknown. Motivated by these ﬁndings and the desire to
learn more about the interplay between α-syn phosphorylation,
PLK2, and neurodegeneration, we sought to investigate the effect
of PLK2 expression and PLK2-induced phosphorylation on α-syn
physiology and toxicity in vitro and in vivo.
In the present study, we provide evidence that PLK2 binds
directly to α-syn in an ATP-dependent manner and regulates
α-syn selective clearance via the lysosome–autophagic degra-
dation pathway. PLK2-mediated α-syn degradation is depen-
dent on both PLK2 kinase activity and PLK2/α-syn protein–
protein interaction. Moreover, we show that PLK2 WT, but not
the kinase dead mutant, decreases α-syn protein levels in a rat
genetic model of PD, reverses α-syn–induced toxicity, and
prevents the motor deﬁcits caused by the overexpression of
human α-syn. Consistent with the role of PLK2 on α-syn deg-
radation found in vitro, this effect depends on S129 phos-
phorylation. Collectively, our data support the neuroprotective
role of PLK2 against PD pathology, which seems to be medi-
ated by selective autophagy clearance of human α-syn, and
suggest that modulating PLK2 activity is a viable therapeutic
strategy for the treatment of PD and related disorders.
Signiﬁcance
Converging lines of evidence suggest that increase in α-syn
levels plays a central role in synucleinopathies pathogenesis.
Therefore, lowering α-syn levels represents a viable thera-
peutic strategy for these disorders. Here, we describe a pre-
viously uncharacterized cellular mechanism controlling the
selective autophagic degradation of α-syn. This effect is gov-
erned by PLK2 kinase activity, phosphorylation of α-syn, and
PLK2/α-syn complex formation. In a rat model of Parkinson
disease, PLK2 overexpression reduces α-syn levels and sup-
presses α-syn–induced toxicity and motor deﬁcits. Collectively,
our data support the neuroprotective role of PLK2 and suggest
that modulating its activity is a viable therapeutic strategy for
the treatment of Parkinson disease and related synucleinopathies.
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Results
PLK2 Promotes Selective Autophagic α-Syn Degradation. In our cell-
culture experiments, we consistently observed that PLK2 WT
overexpression results in a decrease in α-syn levels (Fig. S1). To
conﬁrm this observation and further investigate the effect of
PLK2 overexpression on α-syn protein levels, we used a cell-
based assay, in which α-syn expression plasmid was cotransfected
with increasing amounts of the PLK2 plasmid. As shown in Fig.
1A, increasing the expression of PLK2 induced a signiﬁcant de-
crease in α-syn protein levels, which is detected at an apparent
molecular weight of ∼15 kDa. At the highest levels of PLK2
expression, only a small amount of α-syn remained detectable,
suggesting that PLK2 signiﬁcantly reduced total α-syn protein
levels (Fig. 1A). Using different α-syn antibodies directed against
N- or C-terminal epitopes, we ruled out the possibility that the
decrease of α-syn signal could be due to loss of antibody epitope
recognition (Fig. 1A). Using a pS129-speciﬁc antibody, we also
observed a decrease of pS129 levels. This decrease of pS129
levels, inversely correlating with increasing levels of PLK2 kinase
expression, indicates that pS129 α-syn is likely to be a major
target for PLK2-mediated degradation (Fig. 1A).
To determine the mechanism by which α-syn protein is de-
graded, we used a pharmacological approach to selectively block
the different protein-degradation pathways. Interestingly, treat-
ment of cells with the proteasome inhibitors epoxomicin (50 nM)
or MG132 (10 μM) had no effect on PLK2-mediated degrada-
tion of α-syn (Fig. 1B). However, blocking the early and late
stages of the autophagy–lysosomal pathway, using 3MA (10 mM)
and NH4Cl (25 mM), respectively, restored α-syn amount to the
same level as the condition without PLK2 (Fig. 1B). Together,
these data demonstrate that PLK2 overexpression enhances
α-syn clearance via the lysosome–autophagy pathway.
To assess whether other members of the synuclein family
could also be targeted by PLK2 for protein degradation, we
coexpressed PLK2 with β-synuclein (β-syn), which we showed
previously to be a substrate of PLK2 (13). Interestingly, PLK2
overexpression signiﬁcantly decreased the levels of β-syn (Fig.
1C) but did not affect the expression levels of a nonrelated cy-
tosolic protein Green Fluorescent Protein (GFP) (Fig. 1D). This
observation suggests that PLK2 can mediate the degradation of
phosphorylated synuclein substrates.
Next, we sought to determine whether enhancing autophagic
degradation of α-syn is a speciﬁc feature of PLK2, or could be
induced by any of the enzymes that are able to catalyze α-syn
phosphorylation at S129. In particular, we assessed the effect of
members of the G protein-coupled receptor kinase (GRK)
family, which have been reported to phosphorylate human α-syn
at S129 (21, 22). The results shown in Fig. 2 A and B demonstrate
that the overexpression of PLK2 only, but not GRK3, -5, or -6,
induced a signiﬁcant decrease of α-syn protein levels. In partic-
ular, GRK5 and -6 even induced a signiﬁcant increase in the
level of human α-syn (Fig. 2 A and B). Evaluation of pS129 levels
conﬁrmed the superiority of PLK2 in catalyzing α-syn phos-
phorylation (Fig. 2C). These results suggest that, although vari-
ous kinases can phosphorylate α-syn at S129, only PLK2 activity
increases the turnover of synuclein substrates via autophagy.
PLK2/α-Syn Complex Formation and PLK2 Kinase Activity Are Essential
for PLK2-Mediated α-Syn Degradation. To investigate whether a
protein–protein interaction exists between PLK2 and α-syn and
modulates PLK2-mediated α-syn degradation, we ﬁrst assessed
the direct binding between the two proteins in a cell-based assay.
Because PLK2 interaction with several substrates has been
reported to be ATP-dependent (23), coimmunoprecipitation was
performed in the presence or absence of ATP. We observed that
PLK2 immunoprecipitated with α-syn only in the presence of ATP
(Fig. 3A), indicating that a direct ATP-dependent interaction exists
between the two proteins.
Given that ATP is also important for α-syn phosphorylation by
PLK2, we investigated whether α-syn phosphorylation and the
integrity of PLK2 kinase domain are important for PLK2/α-syn
interaction. A pull-down assay showed that the substitution of
Serine 129 to Alanine in α-syn structure abolished the PLK2/
α-syn protein–protein interaction (Fig. 3B). Using the kinase
dead mutant form of PLK2 (PLK2 KDM) (Fig. S1), we also
observed a loss of interaction between α-syn and PLK2 KDM
(Fig. 3B). Collectively, these results indicate that α-syn binds
directly to PLK2 in an ATP-dependent manner and that the
integrity of α-syn phosphorylation site S129 and PLK2 kinase
domain are important for this interaction.
To evaluate whether α-syn and PLK2 interaction is essential
for α-syn clearance, we decided to expose the α-syn/PLK2 com-
plex to competitive interactors, namely, the alternative PLK2
substrates β-syn (13) and spine-associated Rap guanosine tri-
phosphatase-activating protein (SPAR) (24). First, using a pull-
down assay, we veriﬁed that PLK2/α-syn complex formation was
reduced in the presence of β-syn or SPAR (Fig. 3C), conﬁrming
that the presence of β-syn or SPAR can effectively compete with
the PLK2/α-syn interaction. Next, cells were cotransfected with
Fig. 1. PLK2 overexpression enhances α-syn autophagy-mediated degra-
dation in a cell-based assay. (A) Western blot and quantiﬁcation of whole-
cell lysate from HEK cells transfected with human α-syn (1 μg) and increasing
amounts of PLK2 WT (0.5, 1, and 2 μg). For DNA titrations, total DNA per
transfection was equalized by addition of pcDNA empty vector. The over-
expression of PLK2 induced a concentration-dependent decrease of α-syn
protein levels. The detection of α-syn using antibodies targeting different
epitopes on α-syn ruled out the possibility of loss of epitope recognition
(**P < 0.01). (B) Whole-cell lysate form HEK cells transfected with α-syn
(1 μg) and PLK2 WT (0.5 μg) and treated with proteasome inhibitors (50 nM
Epoxomicin and 10 μMMG132) and autophagy–lysosome inhibitors (10 mM
3MA and 25 mM NH4Cl). Western blot and optical density quantiﬁcation
showed that only autophagy–lysosome inhibitors reverse PLK2-induced re-
duction of α-syn (**P < 0.01). (C) Whole-cell lysate analysis and optical-density
quantiﬁcation showing that β-synuclein (β-syn) is degraded after PLK2 over-
expression (**P < 0.01). (D) Whole-cell lysate analysis and optical density
quantiﬁcation showing that GFP levels are not affected by PLK2 overexpression.
E3946 | www.pnas.org/cgi/doi/10.1073/pnas.1309991110 Oueslati et al.
α-syn, PLK2, and increasing concentrations of plasmids encoding
either β-syn (Fig. 3D) or SPAR (Fig. 3E). Interestingly, com-
petitive inhibition reversed PLK2-mediated α-syn degradation
in a concentration-dependent manner (Fig. 3 D and E). Collec-
tively, these data indicate that PLK2/α-syn complex formation is
essential for PLK2-mediated α-syn degradation.
Strikingly, evaluation of the pS129/α-syn ratio revealed similar
levels of the phosphorylated form in the presence or absence of
competitors β-syn or SPAR (Fig. 3 D and E). This observation
indicates that, despite the disruption of the PLK2/α-syn complex
and the suppression of α-syn degradation, the extent of α-syn
phosphorylation at S129 remained unchanged, demonstrating
that α-syn phosphorylation at S129 is essential but not sufﬁcient
for PLK2-mediated α-syn clearance.
Then, to investigate whether the kinase activity is required for
PLK2-mediated α-syn degradation, we used two approaches: (i)
a genetic approach by using the kinase dead mutant (PLK2 KDM)
and (ii) a pharmacological approach by using a potent and selective
ATP competitor, BI2536, which inhibits PLK2 activity (14). After
overexpression of the kinase dead mutant form of PLK2 (PLK2
KDM), which failed to interact with α-syn, α-syn protein levels
remained unchanged, in contrast to the reduced α-syn levels ob-
served with PLK2 WT (Fig. 4 A and B). Moreover, when cells
overexpressing PLK2 were treated with BI2536, we observed a re-
duction of pS129 levels, demonstrating the inhibition of PLK2
kinase activity (Fig. 4C). Remarkably, BI2536 also reversed PLK2-
mediated α-syn degradation (Fig. 4C). These data indicate that
PLK2 kinase activity is essential for PLK2-mediated α-syn clear-
ance. It is worth noting that the genetic and the pharmacological
inhibition of PLK2 activity induced an accumulation of PLK2
protein levels (Fig. 4 A and C), conﬁrming that PLK2 autophos-
phorylation controls its self-degradation (19). Collectively, our data
suggest that the formation of the PLK2/α-syn complex and PLK2
kinase activity are essential for PLK2-mediated α-syn degradation.
PLK2 WT, but Not the Kinase-Dead Mutant, Induces the Phosphorylation
of Human α-Syn and Reduces Its Accumulation in Vivo. To investigate
whether PLK2 catalyzes α-syn phosphorylation at S129 and
modulates its expression levels in the nigral dopaminergic neu-
rons, we used a genetic rat model of PD, in which human α-syn
was cooverexpressed with either PLK2 WT or KDM, using an
adeno-associated virus (AAV) gene-delivery system. To keep the
total amount of injected viral particles constant in all conditions,
we coinjected the vector encoding α-syn with an empty vector
(Stuffer) in the control group.
Four months postinjection, histological evaluation of trans-
gene expression conﬁrmed the detection of human α-syn or
PLK2 immunoreactivity exclusively in the correspondent injected
midbrain (Fig. 5A). Coimmunoﬂuorescence analysis revealed
that, in animals injected with both vectors, the infected PLK2-
positive neurons coexpress α-syn (Fig. S2). At high magniﬁca-
tion, the analysis revealed α-syn and PLK2 colocalization in the
cytoplasmic compartment (Fig. 5B).
Then, using antibodies directed against pS129 and tyrosine
hydroxylase (TH), a marker of the dopaminergic neurons, cos-
taining revealed that the majority of pS129-positive neurons were
dopaminergic and that the levels of pS129 were dramatically in-
creased when α-syn was cooverexpressed with PLK2 WT, but not
with PLK2 KDM or the empty vector (Fig. S3). Semiquantitative
estimation of pS129 levels, by the evaluation of pS129 relative
ﬂuorescence intensity in individual neurons, with respect to total
α-syn, revealed threefold increase when PLK2 WT is coexpressed
with α-syn, indicating that PLK2 phosphorylates α-syn efﬁciently
in rat dopaminergic neurons (Fig. 5 C and D).
Then we investigated whether PLK2 overexpression could
induce a decrease of α-syn protein levels, similarly to what we
observed in cell culture assays. Quantiﬁcation of ﬂuorescent
signal intensity of human α-syn in the injected midbrains showed
that PLK2 WT overexpression reduced intraneuronal α-syn
protein levels by 55.8%, in contrast to PLK2 KDM, which did
not affect α-syn signal (Fig. 5 E and F). These results demon-
strate that PLK2 kinase activity is required for regulating human
α-syn protein levels in rat midbrains, consistent with our cell
culture results. The distribution of α-syn signal intensity per
neuron demonstrates that the decrease of α-syn levels is ho-
mogenous among the population of dopaminergic neurons, as
reﬂected by the shift of the entire cell population toward lower
signal intensity, indicating that α-syn protein levels decreased in
the majority of the coinfected neurons (Fig. 5G).
PLK2 WT, but Not the Kinase-Dead Mutant, Suppresses α-Syn–Induced
Toxicity and Motor Deﬁcits in Vivo. To assess whether the PLK2-
mediated reduction of α-syn protein levels, in the midbrain
neurons, is associated with a modulation of α-syn–induced neu-
ronal toxicity, we estimated the total number of the TH-positive
neurons per SNc, using unbiased stereological quantiﬁcation. We
ﬁrst sought to evaluate the toxic effect induced by α-syn and
PLK2 (WT and KDM) overexpressed separately in rat midbrain.
Unbiased cell quantiﬁcation revealed an extensive loss of TH-
positive neurons in the injected SNc after α-syn overexpression
(36.2% ± 2.7%, versus the noninjected hemisphere; n = 8) (Fig.
S4). This neuronal loss was accompanied by the induction of
hemiparkinsonian motor impairment (Fig. S4). In contrast,
neither the vector overexpressing PLK2 WT, nor the KDM,
caused any comparable neuron loss (13.3% ± 2.7%, n = 8 and
10.3% ± 1.9%, n = 8, respectively) or motor dysfunction (Fig.
S4). In addition, we found no difference between the active and
kinase-dead forms, indicating that kinase activity had no signif-
icant role in the observed minor neuron loss. These data conﬁrm
the toxicity of overexpressed α-syn (25, 26) and demonstrate
that PLK2 overexpression is not toxic under our experimental
conditions.
Then, we evaluated the toxicity induced by the cooverexpression
of α-syn with PLK2. Interestingly, when injected in combination
with the noncoding vector or PLK2 KDM, α-syn overexpression
induced a signiﬁcant neuronal loss (32.5% ± 2.1%, n = 9 and
33.5% ± 3%, n = 9, of TH-positive neurons loss, respectively)
(Fig. 6 A and B). However, the coexpression with PLK2 WT
signiﬁcantly reduced the α-syn–induced loss of DA neurons to
12.6% ± 2.3% (n= 8) (P < 0.01, versus the two other conditions)
(Fig. 6 A and B). Quantiﬁcation of TH-positive ﬁbers in the
striatum conﬁrmed this result, as striatal projections were almost
completely preserved in the PLK2 WT/α-syn group, compared
Fig. 2. PLK2 overexpression, but not the GRKs, mediated α-syn degradation
in HEK239T cells. (A) Whole-cell analysis and Western blot illustrating the
levels of total α-syn and pS129 in HEK cells transfected with α-syn and PLK2
or GRKs (GRK3, GRK5, and GRK6). (B) Optical-density quantiﬁcation of α-syn
signal showing that only the overexpression of PLK2 induced a decrease of
α-syn levels. Interestingly, GRK5 and GRK6 induced an increase of α-syn
signal (*P < 0.05; **P < 0.01). (C) Optical-density quantiﬁcation of pS129
levels, relative to total α-syn signal, showing the superiority of PLK2 in
phosphorylating α-syn in cell culture (**P < 0.01).
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with the coinjection of the α-syn vector with the stuffer and
PLK2 KDM vectors (P < 0.01) (Fig. 6 C and D). These data
demonstrate that the kinase activity of PLK2 suppresses human
α-syn toxicity in vivo. Previous studies from our group and others
have established that the decrease in TH+ neuron number, induced
by α-syn overexpression in this rat model, is due to neuronal loss
rather than the loss of dopaminergic phenotype. In these studies,
quantiﬁcation of Nissl-positive or cresyl violet-positive cells in
the SNc revealed a reduction of the number of positive cells,
after α-syn overexpression, compared with the noninjected side,
conﬁrming that the neurons had indeed degenerated (25, 27).
To determine whether PLK2-mediated protection against α-syn
toxicity is associated with improvement of α-syn–induced motor
impairments, we assessed the symmetry of forelimb activity in
each group using the cylinder test. Four months postinjection,
rats overexpressing human α-syn in combination with the non-
coding vector or PLK2 KDM exhibited a signiﬁcant reduction in
the use of contralateral forepaws, as compared with their per-
formance measured before vector injection (Fig. 6E). In contrast,
the coexpression of PLK2WT fully rescued contralateral forelimb
motor activity, as animals in the group PLK2 WT/α-syn remained
symmetrical over the entire experiment time course (P < 0.01;
compared with Stuffer/α-syn and PLK2 KDM/α-syn) (Fig. 6E).
Together, these datademonstrate thatPLK2WToverexpression, but
not the kinase dead form, reduces signiﬁcantly α-syn protein levels
in a PLK2 activity and an α-syn phosphorylation-dependent manner
and suppresses neuronal degeneration and hemiparkinsonian motor
symptoms induced by α-syn overexpression.
PLK2 WT Does Not Rescue the Toxic Effects of S129A α-Syn. To de-
termine whether α-syn phosphorylation at S129 is required for
the neuroprotective effects of PLK2 and the reduction of intra-
neuronal levels of α-syn, we overexpressed the S129A mutant
form of human α-syn (to block α-syn phosphorylation at serine
Fig. 3. PLK2/α-syn complex formation is required for PLK2-mediated α-syn turnover. (A) Coimmunoprecipitation of α-syn and PLK2 in the presence or absence
of ATP, showing that the presence of ATP is required for the stabilization of PLK2 and α-syn protein–protein interaction. (B) Coimmunoprecipitation of α-syn
(WT and S129A) with PLK2 (WT and KDM), showing that the integrity of α-syn phosphorylation site S129 and PLK2 kinase domain are important for PLK2/
α-syn interaction. (C) Coimmunoprecipitation of α-syn and PLK2 in the presence of β-syn or SPAR, showing that the presence of one of these two PLK2
substrates competes with α-syn for the interaction with PLK2 and reduces PLK2/α-syn coimmunoprecipitation. (D) Whole-cell lysate form HEK cells transfected
with human α-syn (1 μg), PLK2 WT (0.5 μg), and increasing amounts of β-syn (1.5 and 3 μg). For DNA titrations, total DNA per transfection was equalized by
addition of pcDNA empty vector. The Western blot revealed that the overexpression of β-syn reverses α-syn turnover without affecting pS129/α-syn levels
(*P < 0.05). (E) Whole-cell lysate form HEK cells transfected with human α-syn (1 μg), PLK2 WT (0.5 μg), and increasing amounts of SPAR (1.5 and 3 μg). For
DNA titrations, total DNA per transfection was equalized by addition of empty pcDNA empty vector. The Western blot revealed that the overexpression of
SPAR reverses α-syn turnover without affecting pS129/α-syn levels (*P < 0.05; **P < 0.01).
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129), in combination with PLK2 WT or PLK2 KDM. Four months
postinjection in the rat SNc, we detected by immunohistochemistry
midbrain expression of human α-syn and PLK2 only in injected
hemispheres (Fig. 7A). Immunoﬂuorescence revealed that a sig-
niﬁcant subpopulation of neurons in the SNc coexpressed both
human α-syn S129A and PLK2 (Fig. S5), which were colocalized
in the cytoplasm (Fig. 7B).
Quantitative estimation of total α-syn levels per neuron in brain
samples injected with the S129A α-syn vector, in combination with
empty vector or PLK2, showed that the level of S129A α-syn
remained similar across experimental conditions (Fig. 7 C and D),
with a similar distribution of S129A α-syn expression levels among
the dopaminergic neuronal population (Fig. 7E). Together, these
data demonstrate that phosphorylation at S129 is essential for
PLK2-mediated α-syn turnover in vivo.
Assessment of dopaminergic neuron loss showed that coin-
jection of the S129A α-syn vector with the noncoding vector led
to 49.1% ± 8.3% (n = 5) TH-positive neuron loss in the injected
SNc (Fig. 8 A and B). Remarkably, when the mutated α-syn vector
was injected in combination with PLK2 vectors (WT or KDM), the
extent of neuronal loss was very similar (43.8% ± 7.2%, n = 6 and
40.3% ± 3.5%, n = 5, TH loss, respectively) (Fig. 8 A and B).
Moreover, the analysis of TH-positive ﬁber loss in the striatum
also showed similar and extensive dopaminergic degeneration in
all experimental conditions (Fig. 8 C and D). Interestingly, the
induction of motor deﬁcits, expressed as the percentage of ipsi-
lateral asymmetry in the use of forelimbs in the cylinder test,
further conﬁrmed the absence of any neuroprotective effect of
PLK2 against S129A α-syn toxicity (Fig. 8E).
Collectively, our data conﬁrmed the toxic effect of S129A
α-syn overexpression in the rat SNc, as previously described (26, 28).
Importantly, PLK2 overexpression did not reverse S129A toxicity,
thereby indicating that the neuroprotective effects of PLK2 are
mediated via α-syn phosphorylation at residue S129.
Discussion
Although phosphorylated α-syn at S129 accumulates in aged
brains (20) and over the course of PD pathogenesis (29) and is
localized within Lewy bodies in synucleinopathy-diseased brains
(8, 9) and in transgenic mice models of PD (7, 10–12), its role in
modulating α-syn physiology and toxicity in vivo remains elusive.
Fig. 4. PLK2 kinase activity is required for PLK2-mediated α-syn turnover. (A)
Whole-cell lysate Western blot and (B) optical-density analysis showing that the
overexpression of PLK2 KDMdid not induce α-syn turnover. (C) Whole-cell lysate
Western blot and (D) optical-density analysis showing that inhibition of PLK2
kinase activity, using the ATP-competitive inhibitor BI2536 (10 μM), decreases
pS129 levels and suppresses PLK2-mediated α-syn turnover (**P < 0.01).
Fig. 5. PLK2 WT overexpression, but not the KDM, induces α-syn phos-
phorylation at S129 and reduces intraneuronal α-syn protein levels. (A)
Photomicrographs illustrating the expression of α-syn and PLK2 in the
injected brains. (Scale bar: 50 μm.) (B) A high-magniﬁcation illustration of α-syn
and PLK2 colocalization in a coinfected dopaminergic neuron. (Scale bar: 5
μm.) (C ) Immunoﬂuorescence of α-syn and pS129 showing the increase of
pS129 levels after cooverexpression with PLK2 WT. (Scale bar: 100 μm.)
(D) Optical-density quantiﬁcation of pS129 levels, compared with total
α-syn, estimating threefold increase of pS129 levels after cooverexpression
of α-syn with PLK2 WT and histogram illustrating pS129 levels, relative to
total α-syn. (E ) High-magniﬁcation confocal images illustrating the pop-
ulation of neurons exhibiting α-syn intensity around the median line of the
histograms of frequency distribution (Scale bar: 5μm). (F) Quantiﬁcation,
using ImageJ software, of α-syn protein levels per neuron showing that
α-syn levels are signiﬁcantly decreased when α-syn is cooverexpressed with
PLK2 WT, compared with α-syn + Stuffer or α-syn + PLK2 KDM. (G) Histo-
grams of frequency distribution of labeling, showing the distribution of
α-syn signal intensity in the dopaminergic neuronal population (**P < 0.01).
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Recently, a growing body of evidence suggests that α-syn and
its natural kinase, PLK2, could play synergistic roles in the
modulation of α-syn physiology and toxicity during PD patho-
genesis: (i) PLK2 is the most efﬁcient kinase phosphorylating
α-syn speciﬁcally at S129 in vitro (15), in cell culture (13), and in
vivo (14); (ii) α-syn and PLK2 levels are up-regulated during aging
(20) and in synucleinopathy-diseased brains and transgenic mice
models of PD (13); and (iii) PLK2 is involved in the phosphor-
ylation of aggregated α-syn in vitro (13) and in cell culture (30).
Collectively, these observations suggest a synergic role of PLK2
and α-syn in health and disease states.
α-Syn Directly Binds to PLK2 in an ATP-Dependent Manner. A recent
study reported a weak and transient interaction between α-syn
and PLK2 in a cell-based assay. Detection of this interaction was
possible only in the presence of chemical cross-linkers (31).
Here, we report a direct binding of these two proteins, which is
stabilized in the presence of ATP. This type of protein in-
teraction ATP-dependent has been also described for another
PLK2 substrate in neurons, N-ethylmaleimide-sensitive fusion
protein (NSF) (23), suggesting that PLK2 enzymatic activity
could modulate its interaction with the substrates. Moreover, we
observed that the integrity of α-syn phosphorylation site S129
and PLK2 ATP-binding pocket are important for driving PLK2/
α-syn interaction, suggesting that phosphorylation and ATP bind-
ing induce structural and conformational changes in α-syn and
PLK2, respectively (32, 33), and facilitate the physical interaction
between these two partners.
PLK2 Activity Enhances α-Syn Autophagic Clearance in Cell Culture
and in Vivo. Although recent studies have suggested that phos-
phorylation at S129 targets α-syn for degradation by the pro-
teasome (34, 35), we report that PLK2-phosphorylated α-syn is
mainly degraded by the lysosome–autophagy pathway. This ef-
fect depends on PLK2 activity and PLK2/α-syn complex forma-
tion. Interestingly, kinase-mediated enhancement of substrate
turnover appears to be a characteristic of PLK2 physiological
function in vivo, notably the synuclein family. In dividing cells,
PLK2 regulates centriole duplication through phosphorylation-
mediated degradation of Fbxw7 (36). In nondividing cells and in
response to neuronal overactivity, PLK2 interacts, phosphor-
ylates, and targets SPAR for proteasome degradation, resulting
in reduction of dendritic spines and preservation of the synaptic
homeostasis (24, 37, 38). In a recent study, PLK2 overexpression in
vivo promoted ubiquitin-mediated proteasomal degradation of
RasGRF1, a member of the Ras superfamily of small GTPases
implicated in neuronal plasticity, and induced spine remodeling at
the postsynaptic level (39). Collectively, these observations suggest
that PLK2 could regulate α-syn protein levels under nonphysio-
logical conditions, such as a neuronal overactivity or abnormal
intraneuronal increase of calcium concentration, two conditions
where PLK2 expression is up-regulated (Fig. 9) (24, 37).
Then, we conﬁrmed that the kinase-mediated α-syn clearance
is a unique feature of PLK2, among other α-syn natural kinases.
Indeed, our data demonstrated that only PLK2 overexpression,
but not GRKs (GRK3, GRK5, and GRK6), induces a decrease
of α-syn protein levels in cell culture. Interestingly, analysis of
pS129 levels conﬁrmed the superiority of PLK2 in phosphory-
lating α-syn, suggesting that the speciﬁcity of PLK2 in regulating
α-syn levels could be, in part, related to its ability to more efﬁ-
ciently phosphorylate α-syn in vivo. Together, these results describe
a previously uncharacterized molecular mechanism controlling
α-syn protein levels in which PLK2 interacts with α-syn and
enhances its autophagic clearance. This mechanism could play an
important role in regulating neuronal homeostasis.
PLK2 Overexpression Suppresses α-Syn Toxicity in Rat Midbrain. The
increased levels of PLK2, in aged brains and in Alzheimer’s
disease and PD-diseased brains, suggests that up-regulation of
this kinase may play an important role in the pathogenesis of
synucleinopathies (13, 20). Interestingly, in the present study and
under the experimental conditions used, we report that PLK2
(WT or KDM) overexpression, in rat midbrain, did not induce
any signiﬁcant toxicity on the dopaminergic neurons, suggesting
that PLK2 accumulation is not toxic per se and may not be
deleterious during PD pathogenesis. Previous studies have
shown that PLK2 plays important roles in the regulation of
postsynaptic homeostasis in response to neuronal overactivity, by
remodeling dendritic spine morphology (19, 23, 24, 39), thus
suggesting that the observed accumulation of PLK2 in diseased
brain could be due to the induction of its expression in adult
brain after age-related synaptic dysfunction (40) and/or by the
impairment of protein degradation observed in synucleinopathy-
diseased brains (41).
Interestingly, when overexpressed with α-syn, PLK2 induces a
signiﬁcant increase of pS129 levels (∼threefold) and protects
against α-syn-induced toxicity and motor impairment in vivo.
Our ﬁndings are in accordance with previous work by Gitler
et al., where they identiﬁed CDC5, the yeast ortholog of PLK2,
as suppressor of α-syn toxicity in a yeast model of PD (42). This
observation was also conﬁrmed in rat-midbrain neuronal culture
and in a transgenic worm model of PD, in which the overexpression
of human PLK2 rescues A53T α-syn–induced neurodegeneration
(42). In our rat model, PLK2-mediated neuroprotective effect is
Fig. 6. PLK2 WT overexpression, but not the KDM, suppresses α-syn toxicity
in vivo and alleviates hemiparkinsonian motor deﬁcits. (A) Photomicro-
graphs and (B) stereological quantiﬁcation of the dopaminergic neurons in
the injected SNc. (Scale bar: 1 mm.) (B) Quantiﬁcation revealed that α-syn
overexpression, alone or in combination with PLK2 KDM, induced a signiﬁ-
cant dopaminergic cell loss. However, PLK2WT overexpression reverses α-syn
toxicity (**P < 0.01). (C) Illustration of TH innervation density in the striatum
and (D) optical-density quantiﬁcation showed that only the overexpression
of α-syn, but not PLK2 WT or KDM, induced a TH ﬁber loss in the ipsilateral
striatum (*). (**P < 0.01) (Scale bar: 1 mm.) (E) Histograms illustrating the
induction of hemiparkinsonian motor impairment after the overexpression
of human α-syn. Before injection, all of the animals showed equal motor
performances; however, the overexpression of α-syn, with the empty vector
or PLK2 KDM, induced a signiﬁcant decrease of the use of the contralateral
forepaw, reﬂected by the forelimb asymmetry, whereas the overexpression
of PLK2 WT reverses α-syn–induced motor impairment. **P < 0.01.
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correlated with the reduction of intraneuronal levels of human
α-syn in the injected midbrains. Together, these data provide a
molecular rational for PLK2-mediated suppression of α-syn toxicity
and demonstrate that lowering α-syn protein levels under the
threshold of neuronal toxicity could be a viable therapeutic strategy
for the treatment of synucleinopathies. However, it remains also
likely that phosphorylation at S129 further impacts on α-syn prop-
erties, notably by inhibiting α-syn aggregation (32), modulating
its interaction with cellular membranes (43), and attenuating
α-syn–induced trafﬁcking defects between the endoplasmic re-
ticulum and Golgi (44). In addition, we cannot rule out the possible
implication of other PLK2 substrates, which could mediate PLK2
neuroprotective effects via α-syn–independent pathways.
Furthermore, our in vivo data may initially appear to contra-
dict previous results, from animal models of PD in which α-syn
was overexpressed with members of GRKs, reporting that en-
hancing pS129 levels exacerbates α-syn toxicity, but the unique
interaction between PLK2 and α-syn and selective targeting of
α-syn for degradation by PLK2 may explain the discrepancies. In
transgenic Drosophila, the coexpression of α-syn with GRK2
enhances α-syn phosphorylation at S129 and accelerates neuro-
nal loss compared with nonphosphorylated α-syn (45). Recently,
Sato et al. reported that GRK6 overexpression moderately ac-
celerates A53T α-syn toxicity in an AAV-based rat model of PD,
in an α-syn phosphorylation-dependent manner (46). Therefore,
clear discrepancies are found between different kinases with re-
spect to their effect on α-syn toxicity in vivo. However, in our
study, we also ﬁnd that a clear difference exists between PLK2 and
GRK kinases in the impact of these enzymes on α-syn protein
levels in a cell-based assay. Indeed, our data demonstrate that,
whereas PLK2 overexpression reduces α-syn protein levels, GRK3
did not affect α-syn protein levels and GRK5 and GRK6 induced
further accumulation of α-syn in HEK239T cells (Fig. 2 A and B).
This effect could partially explain the discrepancy of the effect of
GRK overexpression on α-syn toxicity in vivo, compared with
PLK2. Moreover, our data support the hypothesis that this effect
could be related to the ability of PLK2 to more efﬁciently phos-
phorylate α-syn in vivo.
Potential Implications for the Physiological Function of α-Syn. Al-
though PLK2 has been reported as the most efﬁcient kinase
phosphorylating α-syn at S129 in vitro and in vivo (13–15), the
physiological role of PLK2-mediated α-syn phosphorylation remains
unknown. In neurons, PLK2 plays an important role in the regu-
lation of postsynaptic density and the preservation of synaptic ho-
meostasis (23, 24, 37–39) whereas α-syn is rather considered to
regulate synaptic transmission at the presynaptic level, by modu-
lating the recycling of synaptic vesicles (47) and neurotransmitter
release (48, 49). Based on these observations, one could speculate
that interactions between these two proteins may play a role in
synaptic homeostasis at the presynaptic level by (i) reducing total
α-syn level which in turn regulates synaptic vesicle trafﬁcking and
neurotransmitter release and/or (ii) modulation of α-syn interac-
tion with other synaptic proteins (50) or its association with mem-
branes (43).
Taken together, these observations suggest that the induction
of PLK2 expression/activity, in response to stress conditions (i.e.,
excitotoxicity), may play an important role in orchestrating global
neuronal synaptic homeostasis by modulating the levels and the
function of α-syn at the presynaptic compartment and the mod-
ulation of postsynaptic scaffolding proteins (SPAR and PSD95)
and receptors and remodeling the dendritic spine morphology.
Further investigations, notably electrophysiological analysis, are
required to conﬁrm this hypothesis.
Implications for PD Pathogenesis and Therapeutic Strategies. Recent
studies suggest PLK2 and pS129 increased levels as age-related
risk factors for synucleinopathies (20) and showed that PLK2
and pS129 colocalize in diseased brains. In this context, our data
suggest that PLK2-induced enhancement of α-syn turnover could
represent a protective strategy against α-syn toxicity by reducing
and maintaining the total protein levels under a pathologic
threshold. Nevertheless, the impairment of the degradation path-
ways observed during PD pathogenesis (51) could lead to the de-
crease of phosphorylated α-syn turnover and the accumulation of
pS129 proteins over the disease time course (Fig. 9) (29). More-
over, despite the increased accumulation of pS129 within LBs, our
results are consistent with the emerging evidence in support of the
Fig. 7. PLK2 WT overexpression did not reduce α-syn protein levels in rat midbrain. (A) Photomicrographs illustrating the expression of α-syn S129A and PLK2
in the injected brains. (Scale bar: 50 μm.) (B) High-magniﬁcation illustrations of α-syn S129A and PLK2 colocalization in a coinfected dopaminergic neuron.
(Scale bar: 5 μm.) (C) High-magniﬁcation confocal images illustrating the population of neurons exhibiting α-syn S129A intensity around the median line of
the histograms of frequency distribution (Scale bar: 5μm). (D) Quantiﬁcation of α-syn S129A protein levels per neurons showing that the protein levels are
similar in all of the experimental conditions. (E) Histograms of frequency distribution of labeling, showing the distribution of α-syn S129A signal intensity in
the dopaminergic neuronal population.
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hypothesis that S129 phosphorylation is not required for LB for-
mation and toxicity and may instead play an important role in
regulating the turnover and physiological properties of the more
soluble forms of α-syn (Fig. 9). Several lines of evidence support
this hypothesis: (i) phosphorylation at S129 and S87 inhibits α-syn
aggregation in vitro and in vivo (25, 32, 52), (ii) phosphorylation at
S129 is not required for α-syn aggregation (53), (iii) α-syn ﬁbrils are
better substrates for kinases that phosphorylate α-syn at S129 (13,
30) (Fig. 9), and (iv) phosphorylation at S129 regulates α-syn
turnover (34), subcellular localization (54), and protein–protein
interactions (50). It is also plausible that the increased phosphor-
ylation of α-syn within α-syn aggregates and LBs may reﬂect an
active process whereby phosphorylation of aggregated α-syn
enhances their clearance by promoting monomer disassociation and
degradation (Fig. 9B).
Collectively, these data suggest that enhancing, rather than
inhibiting, PLK2 activity may constitute a more viable and ef-
fective therapeutic strategy for the treatment of PD and related
disorders, as enhancing S129 phosphorylation results in re-
duction of α-syn levels and inhibition of its aggregation and
toxicity (Fig. 9C). The identiﬁcation of upstream pathways that
regulate PLK2 levels or activity could yield novel therapeutic
targets to modulate PLK2 kinase activity and thereby inhibit or
reverse the aggregation and toxic activity of α-syn.
Materials and Methods
Plasmid Construction and Production of Recombinant AAV2/6 Viral Vectors.
pEGFP-PLK2 WT, pEGFP-PLK2 pdm, pCMV-PLK2 WT, and pCMV-PLK2 1–334
were kindly provided by Ingrid Hoffmann (German Cancer Research Center,
Heidelberg, Germany) (55–57). pCDNA-β-syn was kindly provided by Anita
Sidhu (Laboratory of Molecular Neurochemistry, Washington, DC), and
pCDNA-myc-SPAR plasmid was kindly provided by Christina Spilker (Leibniz
Institute for Neurobiology, Magdeburg, Germany). Human α-syn cDNA was
cloned in the pCDNA6 vector (Invitrogen). The primers used to generate the
different mutant forms of human α-syn and PLK2 are summarized in
Table S1.
To generate plasmids for the production of adeno-associated viral vectors,
the cDNAs encoding human PLK2 WT and the kinase dead mutant (KDM)
were subcloned in the AAV-CMV-MCS shuttle plasmid (Stratagene), using
standard cloning procedures. The cDNA encoding human α-syn was similarly
subcloned in the AAV-PGK-MCS plasmid, where the mouse PGK-1 promoter
replaces the CMV promoter. The production of the recombinant pseudo-
typed AAV2/6 vectors (serotype 2 genome/serotype 6 capsid) was performed
as described previously (58), and relative infectivity titers were determined
as described in ref. 58. A noncoding AAV vector (stuffer) was used as
a control. The ﬁnal viral titers of individual vectors were as follows: Stuffer:
2.66E10 transducing units (TU)/mL; PLK2 WT: 3.79E11 TU/mL; PLK2 KDM:
3.82E11 TU/mL; α-syn WT: 4.49E12 TU/mL and α-syn S129A: 1.6E13 TU/mL.
Stereotaxic Injections.All surgical and behavioral procedures were performed
in accordancewith the Swiss legislation and the European Community council
directive (86/609/EEC) for the care and use of laboratory animals. The
injections were performed under xylazine/ketamine anesthesia as described
by Paleologou et al. (52). Female Sprague–Dawley rats (Charles River Labo-
ratories), weighing 180–200 g at the time of surgery, were placed in the
stereotaxic frame (David Kopf Instruments) and received a unilateral intra-
nigral injection of 2 μL of viral suspension, which corresponds to a total viral
load of 1.5E7 TU (human α-syn or S129A) and 1E7 TU of PLK2 (WT or KDM). In
the condition of combined injection, 1.5E7 TU of α-syn (WT or S129A) was
coinjected with 1E7 TU of PLK2 WT or KDM. As a control group, α-syn (WT or
S129A) was coinjected with 1E7 TU of noncoding vector (Stuffer).
Fig. 8. PLK2 WT overexpression did not rescue S129A-induced toxicity. (A) Photomicrographs and (B) stereological quantiﬁcation of the dopaminergic
neurons in the injected SNc. Quantiﬁcation revealed that α-syn overexpression with empty vector or in combination with PLK2 induced extensive dopami-
nergic lesion. (Scale bar: 1 mm.) (C) Illustration of TH innervation density in the striatum. (D) Optical-density quantiﬁcation showed that α-syn overexpression
with empty vector or PLK2 induced comparable and extensive TH ﬁber loss in the ipsilateral striatum (*). (Scale bar: 1 mm.) (E) Histograms illustrating the
induction of hemiparkinsonian motor impairment after the overexpression of human α-syn in combination with empty vector or PLK2. Four months post-
injection, animals exhibited comparable forelimb asymmetry caused by the dopaminergic cell loss.
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Motor Behavior: Cylinder Test. The cylinder test was performed to evaluate
the motor impairment induced by transgene overexpression by quantifying
the akinesia of the contralateral forelimb as described previously in Oueslati
et al. (25). Brieﬂy, the rats were placed in a 20-cm Plexiglas cylinder and
videotaped for 10–15 min to record their exploratory behavior. A total
number of 30 forepaw contacts made on the cylinder wall with the ipsilat-
eral or the contralateral (impaired) forelimbs were scored, and the asym-
metry in forelimb activity was expressed as the percentage of contacts made
by the left forepaw, contralateral to the site of vector injection, with respect
to the total number of forepaw contacts.
Immunohistochemistry. For immunohistochemistry, the animals were deeply
anesthetized and transcardially perfused with 4% (wt/vol) paraformaldehyde
(PFA; Fluka, Sigma-Aldrich). Rat brains were removed, postﬁxed for 2 h in PFA
4%, and then placed in 25% (wt/vol) sucrose for 2 d. Coronal sections (35 μm
thick) were cut with a microtome (SM2400; Leica), and the slices were stored
at −20 °C in cryoprotection medium. Immunohistochemical analysis was
performed as described previously by Paleologou et al. (52). Brieﬂy, slices
were incubated with primary antibody, anti-tyrosine hydroxylase (1:500;
AB152; Millipore), anti-human α-syn (1:500; LB509; Zymed Laboratories), anti-
human α-syn (1:500; 211; Santa Cruz), or anti-human PLK2 (1:500; Santa Cruz)
and subsequently incubated with secondary antibodies conjugated to Alexa
Fluor-488 or Alexa Fluor-568 (1:1,000; Invitrogen) for immunoﬂuorescence or
with biotinylated secondary antibody (1:200; Vector Laboratories) for 3,3′-
diaminobenzidine tetrahydrochloride (DAB) revelation (Pierce).
Imagingwasperformedona LeicaDMI 4000microscope (Leica LAS software)
equipped with an Olympus AX70 camera. The confocal acquisitions were
obtained on a Zeiss LSM 700 upright confocal microscope (Zen software).
The α-syn ﬂuorescence intensity within substantia nigra neurons was
determined using NIH ImageJ software by analysis of the ﬂuorescence signal
at different sections throughout the entire midbrain region of each rat.
Unbiased Stereological Estimation of Dopaminergic Neurons in the SNc. The
number of nigral neurons was estimated using unbiased stereology according
to the optical fractionator principle described by West (59). Brieﬂy, the
number of TH-immunoreactive neurons was determined every sixth section
covering the entire SNc. The analysis was performed using MBF Stereo In-
vestigator software (version 9.14.5; MBF Bioscience). The parameters used
for the stereological analysis were as follows: grid size, 200 μm × 180 μm;
counting frame, 75 μm × 75 μm; and 2-μm guard zones. The coefﬁcient of
error was <0.1.
Cell Culture, Transfection, and Small-Molecule Treatments. HEK 293T cells were
maintained at 37 °C and 5% CO2 in DMEM (Invitrogen) supplemented with
10% (vol/vol) FBS (Invitrogen) and 1% penicillin/streptomycin. Cells were
transfected with 1 μg of α-syn plasmid and 0.5 μg or increasing plasmid
amount (0.5, 1, and 2 μg) of PLK2 (WT or KDM), using calcium phosphate
transient transfection. For DNA titrations, total DNA per transfection was
equalized by addition of empty pCDNA vector. Four hours posttransfection,
the media were replaced, and cells were incubated for 24 h.
To study the relative implication of the different protein-degradation
pathways, 24 h posttransfection, cells were treated for 6 h with ubiquitin–
proteasome inhibitors Epoxomicin (50 nM; Sigma-Aldrich) or MG132 (10 μM;
Enzo Life Sciences) or with lysosome–autophagy inhibitors 3 Methyladenine
(3MA, 10 mM; Sigma-Aldrich) or NH4Cl (25 mM; Sigma-Aldrich). To phar-
macologically inhibit PLK2, cells were treated for 6 h with BI2536 (10μM;
Sigma). Then, the total protein fraction was collected by harvesting the cells
and lysing them in 1× sample loading buffer. After incubation at 95 °C for
15 min, the samples were electrophoresed on 12% SDS/PAGE.
Immunoprecipitation. Twenty-four hours posttransfection, cells were lysed by
sonication in PLK2 phosphorylation buffer (10 mM Tris·HCl, pH 7.4, 5 mM
EGTA, 2 mMDTT, 25 mM beta-glycerophosphate, 10 mMMgCl2) complemented
with Protease inhibitor (1:200), PMSF (1:300), and phosphatase inhibitor mixture
2 and 3 (1:200; Sigma), in the presence or absence of 2 mM ATP (Sigma). After
centrifugation, cleared lysate was incubated overnight at 4 °C with anti–α-syn
antibody (BD Laboratory). The day after, Deanabeads (Invitrogen) were washed
and equilibrated in lysis buffer and then added to the mixture of cell lysate and
antibody and incubated overnight at 4 °C under rotation. After three washes in
PBS-tween 0.01, beads were incubated with 1× loading buffer at 95 °C for
10 min, and then the samples were electrophoresed on 4–16% SDS/PAGE.
Statistical Analysis. Statistical analysis was performed using one-way ANOVA
followed by the Newman–Keuls post hoc test. Separate analyses were per-
formed between the injected and noninjected side for each group. P < 0.05
was required for rejection of the null hypothesis.
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Fig. 9. Potential role of phosphorylation in the regulation of α-syn turnover,
aggregation, and toxicity. (A) Schematic representation of the α-syn aggre-
gation pathway. A dynamic equilibrium exists between monomeric and
mutimeric forms of α-syn (dimers, trimmers, ...). Deregulation of this equi-
librium promotes the formation of α-syn ﬁbrils and then the development of
abnormal proteinaceous cytoplasmic inclusions, called Lewy bodies. (B)
Schematic diagram depicting the role of phosphorylation in regulating α-syn
aggregation. PLK2- and CK1-mediated phosphorylation of α-syn, at S129 and
S129 + S87, respectively, inhibits α-syn aggregation in vitro and in vivo (25, 32,
52). Moreover, α-syn ﬁbrils could also be directly phosphorylated by PLKs and
GRKs at S129 (13) and by CK1 at S87 and S129 (52). Phosphorylation of ag-
gregated α-syn could result in monomer dissociation or stabilize dissociated
monomers, and then the soluble phosphorylated α-syn is addressed for de-
gradation via autophagy or proteasome degradation pathways or rapidly
dephosphorylated by cytoplasmic phosphatases. (C) Scheme representing the
effect of phosphorylation on α-syn aggregation and toxicity in neurons. Ac-
cumulated α-syn could be phosphorylated by endogenous kinases, notably
GRKs (21, 22), inducing an inhibition of α-syn aggregation and proteasomal
degradation of the soluble phosphorylated monomers (34, 35). Under
stress conditions (e.g., excitotoxicity) and elevation of endogenous con-
centration of calcium, PLK2 expression is induced in neurons (24, 37, 38).
Overexpressed PLK2 interacts, phosphorylates, and induces autophagic
degradation of phosphorylated α-syn. All together, the two phosphory-
lation-mediated pathways result in a signiﬁcant reduction of α-syn protein
levels and inhibition of α-syn aggregation and consequently protect
neurons against α-syn–induced toxicity.
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